Prevalence of combination of functional dyspepsia and irritable bowel syndrome: a meta-analysis of studies using the Rome III–IV Criteria

Cover Page

Cite item

Full Text

Abstract

Aim. To systematize data on the prevalence of the combination of functional dyspepsia (FD) and irritable bowel syndrome (IBS) using the Rome III–IV Criteria.

Materials and methods. A search in electronic databases MEDLINE/PubMed, EMBASE, and Cochrane was conducted. The depth of search was 17 years (from January 2006 to May 2022). Original publications from peer-reviewed periodicals that applied the Rome III–IV Criteria for diagnosis of FD and IBS in an adult patient population with detailed descriptive statistics to allow the resulting data to be included in the meta-analysis were selected for final analysis.

Results. The final analysis included 38 studies involving 17,993 patients with FD and 15,883 patients with IBS. In the overall pool of studies using the Rome III–IV Criteria, the pooled prevalence of FD in patients with IBS was 34.625% (95% confidence interval [CI] 28.159–41.390), and the pooled prevalence of IBS in patients with FD was 37.549% (95% [CI] 31.511–43.787). A random-effects model was used in the analyses since significant heterogeneity between results was found (p<0.0001; I2>98%). Using the Rome III Criteria, the pooled prevalence of FD in patients with IBS was 31.993% (95% CI 26.135–38.150; I2=98.17%), while the prevalence of IBS in patients with FD was 34.694% (95% [CI] 29.319–40.273; I2=97,89%). An analysis of papers using the Rome IV Criteria demonstrated that the pooled prevalence of FD in patients with IBS was 42.614% (95% CI 18.588–68.675; I2=98.97%), and the prevalence of IBS in patients with FD was 50.444% (95% CI 37.956–62.904; I2=94,39%).

Conclusion. This meta-analysis demonstrated that the prevalence of the combination of FD and IBS identified using the Rome III–IV Criteria is high and is reported in approximately 1 in 3 patients with the functional gastrointestinal disorders concerned. The prevalence of a combination of FD and IBS identified using the Rome IV Criteria is at least 10% higher than that using the Rome III Criteria.

About the authors

Dmitry N. Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Dmitry S. Bordin

Yevdokimov Moscow State University of Medicine and Dentistry; Loginov Moscow Clinical Scientific Center; Tver State Medical University

Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-2815-3992

д-р мед. наук, проф. каф. пропедевтики внутренних болезней и гастроэнтерологии; зав. отд. патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта; проф. каф. общей врачебной практики и семейной медицины

Russian Federation, Moscow; Moscow; Tver

Elena S. Vyuchnova

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-3842-0452

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Ekaterina G. Lebedeva

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-9572-1932

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Diana T. Dicheva

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-9224-7382

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Renata M. Umyarova

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-9390-8303

клин. ординатор каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Igor V. Maev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

References

  1. Андреев Д.Н., Заборовский А.В., Трухманов А.С., и др. Эволюция представлений о функциональных заболеваниях желудочно- кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):4-11 [Andreyev DN, Zaborovsky AV, Trukhmanov AS, et al. Evaluation of the functional gastrointestinal diseases concept from standpoints of Rome IV (2016) diagnostic criteria. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):4-11 (in Russian)]. doi: 10.22416/1382-4376-2017-27-1-4-11
  2. Black CJ, Drossman DA, Talley NJ, et al. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664-74. doi: 10.1016/S0140-6736(20)32115-2
  3. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035
  4. Маев И.В., Андреев Д.Н., Дичева Д.Т., и др. Функциональная диспепсия: современное состояние проблемы. Медицинский вестник МВД. 2013;4:38-45 [Maev IV, Andreev DN, Dicheva DT, et al. Functional dyspepsia: the current state of the problem. Medicinskii Vestnik MVD. 2013;4:38-45 (in Russian)].
  5. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М.: Прима Принт, 2019 [Maev IV, Cheremushkin SV, Kucheriavyi IuA, Andreev DN. Sindrom razdrazhennogo kishechnika s pozitsii sovremennoi fundamental'noi i klinicheskoi meditsiny. Moscow: Prima Print, 2019 (in Russian)].
  6. Kamiya T, Osaga S, Kubota E, et al. Questionnaire-Based Survey on Epidemiology of Functional Gastrointestinal Disorders and Current Status of Gastrointestinal Motility Testing in Asian Countries. Digestion. 2020;102(1):73-89. doi: 10.1159/000513292
  7. Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689-702. doi: 10.1016/S0140-6736(20)30469-4
  8. Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17. doi: 10.1016/S2468-1253(20)30217-X
  9. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. doi: 10.1053/j.gastro.2020.04.014
  10. Hantoro IF, Syam AF, Mudjaddid E, et al. Factors associated with health-related quality of life in patients with functional dyspepsia. Health Qual Life Outcomes. 2018;16(1):83. doi: 10.1186/s12955-018-0913-z; PMID: 29720190; PMCID: PMC5930843
  11. Sundas A, Sampath H, Lamtha SC, et al. Psychosocial quality-of-life correlates in functional gastrointestinal disorders. Rev Gastroenterol Mex (Engl Ed). 2022:S2255-534X(22)00082-2. doi: 10.1016/j.rgmxen.2022.04.005
  12. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132-43. doi: 10.1111/apt.15325
  13. Lin S, Gao T, Sun C, et al. The association between functional dyspepsia and depression: a meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2019;31(8):911-8. doi: 10.1097/MEG.0000000000001451; PMID: 31162150
  14. Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016;16(1):375. doi: 10.1186/s12888-016-1075-3
  15. Alvaro PK, Roberts RM, Harris JK. A Systematic Review Assessing Bidirectionality between Sleep Disturbances, Anxiety, and Depression. Sleep. 2013;36(7):1059-68. doi: 10.5665/sleep.2810
  16. Wang B, Duan R, Duan L. Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis. Saudi J Gastroenterol. 2018;24(3):141-50. doi: 10.4103/sjg.SJG_603_17
  17. Андреев Д.Н., Кучерявый Ю.А., Маев И.В. Распространенность и риск нарушений сна у пациентов с функциональной диспепсией: метаанализ. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(1):26-30 [Andreev DN, Kucheryavy YuA, Mayev IV. The prevalence and risk of sleep disorders in patients with functional dyspepsia: a meta-analysis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(1):26-30 (in Russian)]. doi: 10.17116/jnevro202112101126
  18. Wang C, Fang X. Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia. J Neurogastroenterol Motil. 2021;27(2):153-64. doi: 10.5056/jnm20175
  19. Sperber AD, Freud T, Aziz I, et al. Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clin Gastroenterol Hepatol. 2022;20(5):e945-56. doi: 10.1016/j.cgh.2021.05.042
  20. Маев И.В., Самсонов А.А., Андреев Д.Н., Кочетов С.А. Дифференцированная тактика лечения синдрома функциональной диспепсии. Медицинский совет. 2012;9:13-20 [Maev IV, Samsonov AA, Andreev DN, Kochetov SA. Differentiated treatment of functional dyspepsia syndrome. Meditsinskiy sovet. 2012; 9:13-20 (in Russian)].
  21. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032
  22. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401-9. doi: 10.1016/j.cgh.2009.07.020
  23. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008;8:43. doi: 10.1186/1471-230X-8-43; PMID: 18808723; PMCID: PMC2569040
  24. Nakajima S, Takahashi K, Sato J, et al. Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol. 2010;25 Suppl. 1:S138-43. doi: 10.1111/j.1440-1746.2010.06244.x; PMID: 20586856
  25. Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25(6):1151-6. doi: 10.1111/j.1440-1746.2010.06249.x; PMID: 20594232
  26. Lee HJ, Lee SY, Kim JH, et al. Depressive mood and quality of life in functional gastrointestinal disorders: differences between functional dyspepsia, irritable bowel syndrome and overlap syndrome. Gen Hosp Psychiatry. 2010;32(5):499-502. doi: 10.1016/j.genhosppsych.2010.05.002; PMID: 20851270
  27. Aro P, Talley NJ, Agréus L, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011;33(11):1215-24. doi: 10.1111/j.1365-2036.2011.04640.x; PMID: 21443537
  28. Fujiwara Y, Kubo M, Kohata Y, et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med. 2011;50(21):2443-7. doi: 10.2169/internalmedicine.50.6012; PMID: 22041340
  29. Park JM, Choi MG, Cho YK, et al. Functional Gastrointestinal Disorders Diagnosed by Rome III Questionnaire in Korea. J Neurogastroenterol Motil. 2011;17(3):279-86. doi: 10.5056/jnm.2011.17.3.279; PMID: 21860820; PMCID: PMC3155064
  30. Piacentino D, Cantarini R, Alfonsi M, et al. Psychopathological features of irritable bowel syndrome patients with and without functional dyspepsia: a cross sectional study. BMC Gastroenterol. 2011;11:94. doi: 10.1186/1471-230X-11-94; PMID: 21871075; PMCID: PMC3175195
  31. Pourhoseingholi A, Vahedi M, Pourhoseingholi MA, et al. Irritable bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: overlap analysis using loglinear models. Arab J Gastroenterol. 2012;13(1):20-3. doi: 10.1016/j.ajg.2012.02.005; PMID: 22560820
  32. Nwokediuko SC, Ijoma U, Obienu O. Functional dyspepsia: subtypes, risk factors, and overlap with irritable bowel syndrome in a population of african patients. Gastroenterol Res Pract. 2012;2012:562393. doi: 10.1155/2012/562393; PMID: 23213327; PMCID: PMC3506890
  33. Futagami S, Yamawaki H, Shimpuku M, et al. Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia. J Nippon Med Sch. 2013;80(5):362-70. doi: 10.1272/jnms.80.362; PMID: 24189354
  34. Rasmussen S, Jensen TH, Henriksen SL, et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162-9. doi: 10.3109/00365521.2014.983157; PMID: 25525975
  35. Xiong LS, Shi Q, Gong XR, et al. The spectra, symptom profiles and overlap of Rome III functional gastrointestinal disorders in a tertiary center in South China. J Dig Dis. 2014;15(10):538-44. doi: 10.1111/1751-2980.12178; PMID: 25102919
  36. Perveen I, Rahman MM, Saha M, et al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3):265-73. doi: 10.1007/s12664-014-0447-1; PMID: 24664445
  37. Yi ZH, Yang ZB, Kang L, et al. [Clinical features, quality of life and psychological health of patients with irritable bowel syndrome and functional dyspepsia]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45(3):493-6 (in Chinese)]. PMID: 24941826
  38. Le Pluart D, Sabaté JM, Bouchoucha M, et al. Functional gastrointestinal disorders in 35,447 adults and their association with body mass index. Aliment Pharmacol Ther. 2015;41(8):758-67. doi: 10.1111/apt.13143; PMID: 25728697
  39. Vargas-Matos I, Ng-Sueng LF, Flores-Arriaga J, et al. Superposición del síndrome de intestino irritable y dispepsia funcional basados en criterios ROMA III en estudiantes de medicina de una universidad privada de Lima, Perú. Rev Gastroenterol Peru. 2015;35(3):129-225 [Vargas-Matos I, Ng-Sueng LF, Flores-Arriaga J, et al. Overlap of irritable bowel syndrome and functional dyspepsia based on Rome III criteria in medical students from a private university in Lima, Peru. Rev Gastroenterol Peru. 2015;35(3):129-225 (in Spanish)].
  40. Kibune Nagasako C, Garcia Montes C, Silva Lorena SL, Mesquita MA. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108(2):59-64. doi: 10.17235/reed.2015.3979/2015; PMID: 26838486
  41. Yao X, Yang YS, Cui LH, et al. The overlap of upper functional gastrointestinal disorders with irritable bowel syndrome in Chinese outpatients: A multicenter study. J Gastroenterol Hepatol. 2016;31(9):1584-93. doi: 10.1111/jgh.13317; PMID: 26875585
  42. Wensaas KA, Hanevik K, Hausken T, et al. Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis. Neurogastroenterol Motil. 2016;28(10):1561-9. doi: 10.1111/nmo.12856; PMID: 27189227
  43. Vakil N, Stelwagon M, Shea EP, Miller S. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J. 2016;4(3):413-22. doi: 10.1177/2050640615600114; PMID: 27403308; PMCID: PMC4924424
  44. Jarbøl DE, Rasmussen S, Balasubramaniam K, et al. Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome – a population based study. BMC Gastroenterol. 2017;17(1):65. doi: 10.1186/s12876-017-0622-9; PMID: 28521729; PMCID: PMC5437406
  45. Ghoshal UC, Singh R. Frequency and risk factors of functional gastro-intestinal disorders in a rural Indian population. J Gastroenterol Hepatol. 2017;32(2):378-87. doi: 10.1111/jgh.13465; PMID: 27262283
  46. Сhoi YJ, Kim N, Yoon H, et al. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. J Gastroenterol Hepatol. 2017;32(9):1553-61. doi: 10.1111/jgh.13756; PMID: 28160607
  47. Kim SY, Choung RS, Lee SK, et al. Self-reported Sleep Impairment in Functional Dyspepsia and Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(2):280-8. doi: 10.5056/jnm17098; PMID: 29605983; PMCID: PMC5885727
  48. Pohl D, Van Oudenhove L, Törnblom H, et al. Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2018;16(11):1745-53.e1. doi: 10.1016/j.cgh.2018.04.034; PMID: 29702295
  49. Yao X, Yang Y, Zhang S, et al. The impact of overlapping functional dyspepsia, belching disorders and functional heartburn on anxiety, depression and quality of life of Chinese patients with irritable bowel syndrome. BMC Gastroenterol. 2020;20(1):209. doi: 10.1186/s12876-020-01357-1; PMID: 32631285; PMCID: PMC7336672
  50. Oshima T, Siah KTH, Yoshimoto T, et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. doi: 10.1111/jgh.15346; PMID: 33197076; PMCID: PMC7753727
  51. Chuah KH, Beh KH, Rappek NAM, Mahadeva S. The Epidemiology and Quality of Life of Functional Gastrointestinal Disorders According to Rome III vs Rome IV Criteria: A Cross-sectional Study in Primary Care. J Dig Dis. 2021;22(3):159-66. doi: 10.1111/1751-2980.12975; PMID: 33595169
  52. Lee JY, Kim N, Park JH, et al. Sex and Gender Differences in Overlap Syndrome of Functional Gastrointestinal Disorder and Effect of Genetic Polymorphisms in South Korea: A Long-term Follow-up Study. J Neurogastroenterol Motil. 2022;28(1):145-58. doi: 10.5056/jnm21047; PMID: 34980697; PMCID: PMC8748849
  53. Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252-62. doi: 10.1016/S2468-1253(18)30003-7; PMID: 29396034
  54. von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. doi: 10.1007/s10620-018-5343-6; PMID: 30368683
  55. Nakov R, Dimitrova-Yurukova D, Snegarova V, et al. Prevalence of Irritable Bowel Syndrome, Functional Dyspepsia and their Overlap in Bulgaria: a Population-Based Study. J Gastrointestin Liver Dis. 2020;29(3):329-38. doi: 10.15403/jgld-2645; PMID: 32919417
  56. Goyal O, Nohria S, Dhaliwal AS, et al. Prevalence, overlap, and risk factors for Rome IV functional gastrointestinal disorders among college students in northern India. Indian J Gastroenterol. 2021;40(2):144-53. doi: 10.1007/s12664-020-01106-y; PMID: 33226570
  57. Li C, Xu J, Yin D, et al. Prevalence and trigger factors of functional gastrointestinal disorders among male civil pilots in China. Sci Rep. 2021;11(1):2021. doi: 10.1038/s41598-021-81825-0; PMID: 33479463; PMCID: PMC7820411
  58. Nam K, Kim N, Song HJ, et al. Gender difference in the overlap of irritable bowel syndrome and functional dyspepsia: a prospective nationwide multicenter study in Korea. J Gastroenterol. 2021;56(6):537-46. doi: 10.1007/s00535-021-01775-2; PMID: 33687537
  59. Barberio B, Yiannakou Y, Houghton LA, et al. Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. Clin Gastroenterol Hepatol. 2022;20(2):e89-101. doi: 10.1016/j.cgh.2021.04.011; PMID: 33839276
  60. Shah A, Gurusamy SR, Hansen T, et al. Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia. Dig Dis Sci. 2022;67(6):2299-309. doi: 10.1007/s10620-021-07149-1; PMID: 34392491
  61. Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut. 1999;44(4):527-33. doi: 10.1136/gut.44.4.527
  62. Маев И.В., Андреев Д.Н., Заборовский А.В., Лобанова Е.Г. Функциональные заболевания желудочно-кишечного тракта: механизмы развития и принципы мультитаргетной терапии. Медицинский совет. 2022;7:8-14 [Maev IV, Andreev DN, Zaborovsky AV, Lobanova EG. Functional gastrointestinal diseases: mechanisms of development and principles of multitarget therapy. Meditsinskiy sovet. 2022;7:8-14 (in Russian)]. doi: 10.21518/2079-701X-2022-16-7-8-14
  63. Маев И.В., Умярова Р.М., Андреев Д.Н., и др. Сочетание функциональной диспепсии и синдрома раздраженного кишечника при использовании Римских критериев IV пересмотра: мета- анализ. Медицинский совет. 2021;5:12-20 [Maev IV, Umyarova RM, Andreev DN, et al. Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis. Meditsinskiy sovet. 2021;5:12-20 (in Russian)]. doi: 10.21518/2079-701X-2021-5-12-20
  64. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-92. doi: 10.1053/j.gastro.2016.02.011
  65. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393-407. doi: 10.1053/j.gastro.2016.02.031
  66. Halder SL, Locke 3 GR, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133:799-807. doi: 10.1053/j.gastro.2007.06.010
  67. Ford AC, Forman D, Bailey AG. Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior. Am J Gastroenterol. 2007;103:1229-39. doi: 10.1111/j.1572-0241.2007.01740.x
  68. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. doi: 10.15829/1728-8800-2021-2758
  69. Андреев Д.Н. Роль нарушения проницаемости слизистой оболочки кишечника в генезе функциональных заболеваний желудочно-кишечного тракта. Consilium Medicum. 2019;21(8):29-34 [Andreev DN. The role of alterations in permeability of the intestinal mucosa in the genesis of functional gastrointestinal disorders. Consilium Medicum. 2019;21(8):29-34 (in Russian)]. doi: 10.26442/20751753.2019.8.190539
  70. Андреев Д.Н., Дичева Д.Т. Нарушение проницаемости слизистой оболочки кишечника как фактор этиопатогенеза функциональных заболеваний желудочно-кишечного тракта. Медицинский совет. 2020;5:87-95 [Andreev DN, Dicheva DT. A breach in the intestinal permeability as a factor of etiopathogenesis of functional gastrointestinal diseases. Meditsinskiy sovet. 2020;5:87-95 (in Russian)]. doi: 10.21518/2079-701X-2020-5-87-95
  71. Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345-9. doi: 10.2147/JIR.S174982
  72. Du L, Chen B, Kim JJ, et al. Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(4):e13304. doi: 10.1111/nmo.13304
  73. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther. 2015;41(2):177-88. doi: 10.1111/apt.13006
  74. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-32. doi: 10.1136/gut.2008.167270; PMID: 19091823
  75. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-74. doi: 10.1038/ajg.2014.195; PMID: 25070054
  76. Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. doi: 10.1002/14651858; CD011194.pub3
  77. Ford AC, Luthra P, Tack J, et al. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66(3):411-20. doi: 10.1136/gutjnl-2015-310721; PMID: 26567029
  78. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233-43. doi: 10.1038/s41395-018-0258-6
  79. Ford AC, Lacy BE, Harris LA, et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21-39. doi: 10.1038/s41395-018-0222-5; PMID: 30177784
  80. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Воспаление, нарушение моторной функции и висцеральная гиперчувствительность: основные механизмы функциональных расстройств желудочно-кишечного тракта (обзор литературы и резолюция Совета Экспертов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(1):7-14 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Inflammation, impaired motor function and visceral hypersensitivity: the main mechanisms of functional disorders of the gastrointestinal tract (materials of the Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(1):7-14 (in Russian)]. doi: 10.22416/1382-4376-2022-32-1-7-14
  81. Ивашкин В.Т., Маев И.В., Шептулин А.А., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):50-61 [Ivashkin VT, Mayev IV, Sheptulin AA, et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50-61 (in Russian)]. doi: 10.22416/1382-4376-2017-27-1-50-61
  82. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95 [Ivashkin VT, Maev IV, Shelygin YuA, et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95 (in Russian)]. doi: 10.22416/1382-4376-2021-31-5-74-95
  83. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Фармакотерапия заболеваний верхних отделов желудочно-кишечного тракта. М., 2021 [Maev IV, Andreev DN, Kucheriavyi IuA. Farmakoterapiia zabolevanii verkhnikh otdelov zheludochno-kishechnogo trakta. Moscow, 2021 (in Russian)].
  84. Шептулин А.А. Современные возможности применения растительного препарата STW 5 в лечении функциональных заболеваний желудочно-кишечного тракта. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):61-5 [Sheptulin AA. Current Prospects of Herbal STW 5 Agent in Treatment of Functional Gastrointestinal Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):61-5 (in Russian)]. doi: 10.22416/1382-4376-2021-31-5-61-65
  85. Allescher HD, Burgell R, Malfertheiner P, Mearin F. Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action. J Gastrointestin Liver Dis. 2020;29(2):227-33. doi: 10.15403/jgld-814
  86. Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther. 2004;20(11-2):1279-87. doi: 10.1111/j.1365-2036.2004.02275.x
  87. Gundermann KJ, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv Ther. 2003;20(1):43-9. doi: 10.1007/BF02850118
  88. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19(3):271-9. doi: 10.1111/j.1365-2036.2004.01859.x
  89. Vinson B. Development of Iberogast: Clinical Evidence for Multicomponent. In.: Botanical Medicine: From Bench to Bedside. Eds. R Cooper, F Kronenberg. New Rochelle (NY): Mary Ann Liebert, Inc. Publishers, 2009.
  90. Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3-4):65-72. doi: 10.1007/s10354-012-0169-x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Evolution of diagnostic criteria for functional dyspepsia and irritable bowel syndrome.

Download (85KB)
Indexing metadata
3. Fig. 2. CONSORT is a diagram detailing the study selection strategy.

Download (129KB)
Indexing metadata
4. Fig. 3. Forest chart showing the pooled prevalence of FD in patients with IBS using the Rome III–IV revision criteria.

Download (203KB)
Indexing metadata
5. Fig. 4. Forest chart showing the generalized prevalence of IBS in patients with FD using the Rome III–IV revision criteria.

Download (224KB)
Indexing metadata
6. Fig. 5. Funnel scatterplot for assessing the likelihood of publication bias in the analysis of the prevalence of FD in patients with IBS using the Rome III–IV criteria.

Download (73KB)
Indexing metadata
7. Fig. 6. Funnel scatterplot to assess the likelihood of publication bias in the analysis of the prevalence of IBS in patients with FD using the Rome III–IV criteria.

Download (80KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies